Professor John Aitken - the Felix™ device Interview

Professor John Aitken, PhD, ScD, FRSE, formerly School of Environmental and Life Sciences (Biological Sciences), University of Newcastle, Australia, and a global leader in Assisted Reproductive Technologies (ART) research was interviewed about the Felix™ device and its potential application in male infertility and the future needs globally of the IVF and ART industries last year while working at the University of Newcastle.

Note: Professor Aitken was appointed Scientific Director at Memphasys on 1 July 2021.  Further details on the appointment are contained in the ASX announcement of 5 July 2021 linked below under ASX News.

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

For investor and media enquiries:
David Tasker, Chapter One Advisors
E: dtasker@chapteroneadvisors.com.au
M: +61 433 112 936

Find

Level 1, 34-36 Richmond Road,
Homebush West, NSW 2140
Australia

Call

Privacy Preference Center